晚时间窗取栓前CT灌注成像:MR CLEAN-LATE二次分析
本研究为MR CLEAN-LATE随机试验的二次分析,纳入313例基于侧支循环选择的晚时间窗前循环大血管闭塞患者,评估CT灌注参数与血管内治疗疗效的交互作用。结果显示,缺血半暗带体积显著修饰血管内治疗与90天功能结局的关联,半暗带≥120 mL者疗效最大,≤72 mL者效应最小;核心梗死体积和错配比无修饰作用。
要点
- 半暗带体积显著修饰血管内治疗与90天功能结局的关联。
- 半暗带≥120 mL者血管内治疗效应最大,ACOR为6.89。
- 半暗带≤72 mL者效应最小,ACOR为0.49,有潜在伤害趋势。
核心结论
- 缺血半暗带体积与血管内治疗效应存在直接交互作用。
- 半暗带≤72 mL者血管内治疗有潜在伤害趋势,需进一步研究。
- 核心梗死体积和错配比在患者选择中似无额外价值。
研究设计与样本
- 多中心随机临床试验MR CLEAN-LATE的二次分析,开放标签治疗、盲法终点。
- 2018年2月2日至2022年1月27日在18家荷兰卒中干预中心开展。
- 纳入502例基于侧支循环选择的晚时间窗前循环大血管闭塞患者,其中313例(62%)有CT灌注结果纳入本分析。
- 患者随机接受血管内治疗联合最佳药物治疗或单纯最佳药物治疗。
主要发现
- 半暗带体积显著修饰血管内治疗与结局的关联(交互作用P < .001)。
- 半暗带≥120 mL者效应量最大,ACOR 6.89(95% CI 2.96-16.04)。
- 半暗带≤72 mL者效应量最小,ACOR 0.49(95% CI 0.22-1.08)。
- 核心梗死体积和错配比未修饰血管内治疗效应。
- 血管内治疗组男性比例低于非血管内治疗组(73/168 [43%] vs 82/145 [57%])。
关键数值与推荐
- 研究纳入标准:前循环大血管闭塞、CT血管成像显示存在侧支血流、晚时间窗(症状发作或最后正常时间后6-24小时)。
临床怎么用
- 在基于侧支循环选择的晚时间窗患者中,CT灌注半暗带体积可能有助于识别血管内治疗获益程度不同的亚组。
- 半暗带≤72 mL者血管内治疗有潜在伤害趋势,需进一步研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: MR CLEAN-LATE (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands for Late Arrivals) showed efficacy of endovascular treatment (EVT) in the late window (6-24 hours after stroke symptom onset or time last seen well) among patients with ischemic stroke selected based on collateral flow. Therefore, the future role of computed tomography perfusion (CTP) imaging in patient selection for late-window EVT may change. OBJECTIVE: To investigate the interaction among CTP parameters (core volumes, penumbra volumes, and mismatch ratio) and the association of EVT with functional outcomes among patients in the late window after ischemic stroke selected based on collateral flow. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc secondary analysis of MR CLEAN-LATE, a multicenter randomized clinical trial, with open-label treatment and blinded end point, conducted from February 2, 2018, to January 27, 2022, in 18 Dutch stroke intervention centers. Participants included 502 patients with anterior circulation large vessel occlusion and present collateral flow on results of computed tomographic angiography in the late window after stroke, who gave deferred consent and were included in MR CLEAN-LATE. All patients had completed follow-up at 90 days. This secondary analysis included 313 patients (62%) with available CTP results. Statistical analysis was performed in September 2023. INTERVENTION: Patients were randomized to receive EVT (EVT group) and best medical management vs best medical management alone (no EVT group). MAIN OUTCOMES AND MEASURES: The primary outcome was functional outcome at 90 days measured by the modified Rankin Scale score. The treatment effect was analyzed in subgroups of core volumes, penumbra volume, and mismatch ratios using ordinal regression analysis. An interaction analysis was performed to assess whether CTP parameters modified the EVT effect on the modified Rankin Scale score at 90 days. All analyses were adjusted for relevant prognostic factors. RESULTS: Among the 313 patients (158 women [50%]) in the study, the median age was 73 years (IQR, 63-80 years), and the EVT group had fewer male participants than the no EVT group (73 of 168 [43%] vs 82 of 145 [57%]). Penumbra volumes significantly modified the association of EVT with outcomes (P < .001 for interaction), with the largest effect size among patients with penumbras of 120 mL or more (adjusted common odds ratio [ACOR], 6.89 [95% CI, 2.96-16.04]) and the smallest effect size among patients with penumbras of 72 mL or less (ACOR, 0.49 [95% CI, 0.22-1.08]). Core volume and mismatch ratio did not modify the EVT effect. CONCLUSIONS AND RELEVANCE: Based on results from this secondary analysis of the MR CLEAN-LATE randomized clinical trial, there was a direct interaction between penumbra volume and treatment effect, and a trend toward potential harm of EVT was seen among patients with the smallest penumbras, which warrants further research. However, core volume and mismatch ratio did not seem to have additional value in patient selection. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN19922220.
引用
- Olthuis SGH, Pinckaers FME, Robbe MMQ, et al. CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment: Secondary Analysis of the MR CLEAN-LATE Randomized Trial. JAMA Neurol. 2025. PMID: 40323620. doi:10.1001/jamaneurol.2025.0716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。